Genentech CFO Lou Lavigne to retire
Thursday, 11 November, 2004
Genentech has announced that its chief financial officer, Lou Lavigne, will retire next March and will be replaced by David Ebersman, currently senior vice president of product operations.
Ebersman joined Genentech in 1994 and was named senior director of product development in 1998, vice president of product development in 1999 and senior vice president of product operations in 2001.
He became a member of Genentech's executive committee in March 2004.
Before joining Genentech, Ebersman was a research analyst covering biotechnology at Oppenheimer & Company, which is now CIBC World Markets. Ebersman will be replaced by Pat Yang, currently vice president of South San Francisco Manufacturing and Engineering.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
